Unit:
Department of ChemistryLibrary of the School of Science
Dissertation committee:
Ευρύκλεια Λιανίδου, Καθηγήτρια Αναλυτικής Χημείας και Κλινικής Χημείας, Τμήμα Χημείας, ΕΚΠΑ.
Χρίστος Παπαδημητρίου, Καθηγητής Θεραπευτικής Ογκολογίας, Ιατρική Σχολή, ΕΚΠΑ.
Αθηνά Μάρκου, Επίκουρη Καθηγήτρια Αναλυτικής Χημείας, Τμήμα Χημείας, ΕΚΠΑ.
Νικόλαος Θωμαΐδης, Καθηγητής Αναλυτικής Χημείας, Τμήμα Χημείας, ΕΚΠΑ.
Τιμοκράτης Καραμήτρος, Κύριος Ερευνητής - Β’ Βαθμίδας, Βιοπληροφορική και Εφαρμοσμένη Γενωμική, Τομέας Μικροβιολογίας, Ελληνικό Ινστιτούτο Παστέρ.
Klaus Pantel, Professor, Director of the Institute of Tumour Biology, University Medical Centre Hamburg Eppendorf, Germany.
Catherine Alix-Panabières, Professor, PU-PH – Oncology, Director of the Liquid Biopsy Laboratory, Faculty of Medicine of Montpellier, France.
Original Title:
Development and clinical evaluation of methods for epigenetic analysis of cell-free DNA (cfDNA) in patients with early prostate cancer
Translated title:
Development and clinical evaluation of methods for epigenetic analysis of cell-free DNA (cfDNA) in patients with early prostate cancer
Summary:
Prostate cancer is one of the most common malignancies in men. Early detection of prostate cancer plays a critical role in improving treatment outcomes. Millions of new cases of prostate cancer are diagnosed worldwide each year, making it a significant and widespread health problem. Early detection is critical for the effective intervention and better patient outcomes. Prostate specific antigen (PSA) is one of the most established and widely used biomarker for prostate cancer screening, but it also has drawbacks such as false positive results and the inability to distinguish between benign and aggressive forms of the disease. In the search for more accurate and reliable diagnostic tools, the field of cancer biomarkers has seen rapid development.
Liquid biopsy analysis is based mainly on the a) detection, enumeration, and molecular characterization of Circulating Tumor Cells (CTCs), b) detection of mutations and epigenetic alterations in plasma cell-free DNA (cfDNA) and c) detection of circulating cell-free microRNAs (ccfmiRNAs). Liquid biopsy is now established as a minimally invasive approach that allows continuous monitoring of patients in real time, and provides important clinical information for prognosis, early detection of Minimal Residual Disease (MRD), treatment selection and early detection of resistance. Recently there are also very promising results on the potential use of liquid biopsy for the early detection of cancer.
Liquid biopsy analysis has become an extremely valuable source of genetic and epigenetic data, offering insights into the molecular landscape of tumors. The main aim of this PhD thesis was the development and clinical evaluation of novel liquid biopsy methodologies for epigenetic analysis of plasma-cfDNA and detection of ccfmiRNAs in patients with early prostate cancer.
Main subject category:
Science
Keywords:
Prostate cancer, cfDNA, ccfmiRNAs, mutations, DNA methylation, epigenetics, sequencing, tumor biomarkers, early detection
Number of references:
277
File:
File access is restricted until 2027-03-28.
PhD 28-3-24.pdf
15 MB
File access is restricted until 2027-03-28.
